BiotechTV - News

BiotechTV
  • 0.0 (0)
  • 生命科学
BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

单集

  1. Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK

    1天前

    Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK

    CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy program, while CSO Sara Prickett explains how the peptide approach aims to teach T-cells to correct allergies while not setting off allergic inflammation that today's therapies do.

    11 分钟
  2. Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development

    1天前

    Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development

    CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead program for ovarian cancer.

    12 分钟
  3. With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space

    2天前

    With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space

    Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA filings and data readouts that Axsome has coming up over the near term. Plus, how he thinks about business development and the big picture.

    23 分钟
  4. Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome

    4天前

    Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome

    He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's non-dilutive financing could help Stoke realize its goal to be a platform company.

    10 分钟
  5. The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy

    4天前

    The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy

    Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations from microdystrophin expression down to muscle integrity are important and pointed in the right direction. Plus, why the company secured a $200M raise before releasing the data publicly.

    25 分钟
  6. Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success

    2月13日

    Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success

    Sponsored Content: She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory expertise, nimbleness, consulting and strategy skills, modeling and biostatistics knowhow, and more.

    10 分钟
  7. Welcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributor

    2月13日

    Welcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributor

    Ryan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.

    5 分钟
  8. Oppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this year

    2月11日

    Oppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this year

    Michael Margolis discusses the macro and policy factors that are in play this year, comments on the China factor, and describes how companies have been trading, and their ability to raise money, off of data.

    15 分钟
  9. John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics

    2月11日

    John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics

    He gives an optimistic take on the sector, describes why he thinks policy reforms can be positive but should be done strategically and carefully, and why he decided to launch City Therapeutics.

    18 分钟
  10. Mizuho Senior Biotech Analyst Salim Syed shares his take on 2025 and key catalysts from companies he covers

    2月11日

    Mizuho Senior Biotech Analyst Salim Syed shares his take on 2025 and key catalysts from companies he covers

    He discusses BridgeBio, Cytokinetics, Wave, Vaxcyte, Iovance, Unity, and Enliven.

    24 分钟
  • 10 集

关于

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

信息

  • 频道
    BiotechTV
  • 创作者
    BiotechTV
  • 活跃年份
    2025年
  • 单集
    10
  • 分级
    儿童适宜
  • 版权
    © BiotechTV
  • 节目网站
    BiotechTV - News

更多来自“BiotechTV”的内容

若要收听包含儿童不宜内容的单集，请登录。

关注此节目的最新内容

登录或注册，以关注节目、存储单集，并获取最新更新。
选择国家或地区

非洲、中东和印度

亚太地区

欧洲

拉丁美洲和加勒比海地区

美国和加拿大